Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380960 | 0.86 | CNR2 (0.38) | EGFRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL4386648 | 0.81 | EGFR (0.45) | EGFRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4381045 | 0.80 | EGFR (0.37) | RECQLEGFRLMNAPDE4APDE4B | |
| SCHEMBL4382088 | 0.80 | EGFR (0.42) | EGFRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4387418 | 0.79 | EGFR (0.44) | EGFRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4386095 | 0.78 | EGFR (0.40) | EGFRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4389199 | 0.77 | EGFR (0.39) | EGFRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4386851 | 0.77 | EGFR (0.36) | EGFRLMNAPDE4APDE4BPDE4C | |
| SCHEMBL4385854 | 0.76 | EGFR (0.48) | EGFRLMNACAPN1 | |
| SCHEMBL4388687 | 0.76 | EGFR (0.43) | EGFRLMNACAPN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | RECQL 1489/4885EGFR 624/4885LMNA 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.